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ABSTRACT
Pseudomonas aeruginosa and Acinetobacter baumannii are Gram-negative bacilli that in the last dec-
ades have become prevalent agents of  hospital infection due to high antimicrobial resistance devel-
oped by these microorganisms. The present study is a retrospective analysis of all positive cultures 
for these microorganisms in the period of January 2004 to December 2008. Resistance levels of A. 
baumannii and P. aeruginosa to carbapenems was high and showed a trend to increase during the 
period of study. In recent years the increasing incidence and resistance levels of A. baumannii and 
P. aeruginosa to the antimicrobials used for their treatment in the hospital setting underscores the 
relevance of infections caused by these bacteria. The selective pressure caused by indiscriminated use 
of broad-spectrum antibiotics in empirical hospital infections is probably the main reason for such 
an increase with the consequent impact upon patient morbidity and mortality.
Keywords: Acinetobacter baumannii, Pseudomonas aeruginosa, drug resistance, carbapenems, hospital 
infection control program.
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INTRODUCTION
Hospital infections are caused by several mi-
croorganisms, being of great relevance the ones 
caused by bacteria. Some of these represent 
higher risk for the patient due to a reduced 
sensibility profi le to antimicrobial agents, as 
observed in glucose non-fermenting Gram-
negative bacilli. In this group, Pseudomonas 
aeruginosa, followed by Acinetobacter bauman-
nii are bacteria largely isolated in hospitals 
worldwide, being associated to high morbidity 
and mortality rates in seriously ill patients.13 
P. aeruginosa and A. baumannii have be-
come increasingly resistant to broad-spectrum 
cephalosporins used in the hospital setting 
leading to the use of more powerful β-lactam 
antibiotics, as the carbapenems.13,15 Currently, 
these agents are important options to treat no-
socomial infections due to their high affi nity 
for type 2 (PBP2) penicillin-binding proteins 
with, stability to many β-lactamases, includ-
ing broad-spectrum (ESBL) and chromosomal 
(AmpC), besides showing excellent permeabil-
ity through bacterial outer membrane.23
Wide use of carbapenems in the hospital 
environment can cause more selective pres-
sure on hospital microbiota, thus enhancing 
the subpopulation of microorganism with 
decreased sensibility or resistance to these 
antibiotics. Currently, bacterial samples of 
P. aeruginosa and A. baumannii resistant 
to most antimicrobial agents and sensitive 
only to polymyxin B have been isolated in 
most of the Brazilian hospitals.5,13
Resistance to carbapenems are thought 
to result from the production of Ambler 
class D and B β-lactamases, also refered to 
as metallo-beta-lactamases (MBL). Addi-
tionally, the production of these enzymes 
has commonly been responsible for the re-
sistance phenotype to these β-lactams.4,21
Due to the potential relevance of the 
evolution of microbial resistance, the ob-
jective of this study was to investigate the 
prevalence of P. aeruginosa and A. bauman-
nii resistant to carbapenems at the Santa Is-
abel Hospital in Blumenau, Santa Catarina 
state, Brazil.
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METHODS
All positive cultures for P. aeruginosa and A. baumannii re-
sistant to carbapenems during the study period of January 
2004 to December 2008 were included. Blood, urine, tracheal 
aspirate, washed bronchi alveolar, sputum, purulent wound, 
skin ulcers, and catheter tip samples collected from patients 
admitted to all units (ICU and other yards) were eligible. 
Data for bacterial identifi cation and sensitivity tests were 
obtained from the records of the Hospital Infection Control 
Commission (HICC). Samples were processed at the local 
microbiology laboratory.
Strains of P. aeruginosa were isolated on chocolate agar, 
blood agar and MacConkey agar based on colony morphol-
ogy, oxidase positive test, and glucose non-fermenting kit 
(Probac).
Strains of A. baumannii were isolated on chocolate agar, 
blood agar and MacConkey agar based on colony morphol-
ogy, negative oxidase test, and glucose non-fermenting kit 
(Probac).
For the sensitivity tests before placing the discs, Mueller-
Hinton plates were inoculated with swabs immersed in the 
inoculation fi nal solution and smeared on the entire plate 
surface. Afterwards, the plates were inverted and incubated 
at 35 ± 2º C for 20 to 24 hours. The sensitivity was investi-
gated using the Kirby-Bauer method for reading the disc dif-
fusion, according to the Clinical and Laboratory Standards 
Institute criteria.3
Annual resistance rates of each microorganism during the 
period of study were tested by the Fischer’s exact test.18 The p-
value for signifi cance was 0.05. Data analysis was performed 
with STATISTICA software, version 6.19
RESULTS
During the studied period 228 strains of P. aeruginosa and 
140 strains of A. baumannii were isolated.
Figures 1 and 2 depicts the sensitivity results of 140 
strains of A. baumannii. In 2004 there was no report of 
resistance to meropenem, whereas 5.13% showed resist-
ance for to imipenem. In 2005, resistance rates signifi cant-
ly increased for both antibiotics: for imipenem it rised to 
55% (p = 0.00003), and for meropenem the rate was 60% 
(p < 0.0001). From 2006 the resistance rates kept gradually 
increasing from 2006 and on, reaching rates of 77.27% to 
imipenem and 80% to meropenem in 2008.
Figures 3 and 4 show the sensitivity results for the 228 
strains of P. aeruginosa. In 2004 there was only 6.06% of re-
sistance to imipenem, rising to 15.38% in 2005 (p = 0.002). 
Rates of resistance to imipenem continued to increase un-
til 2008, when it reached 45.09% (p = 0.02). In relation to 
meropenem, the rate of resistance in 2004 was 6.89%, in-
creased to 12.82% in 2005, and continued to increase until 
2008 (p = 0.0358).
Figure 1: Sensitivity profile of A. baumannii to Imipenem 
from January 2004 to December 2008.
Figure 2: Sensitivity profile of A. baumannii to Meropenem 
from January 2004 to December 2008.
Figure 3: Sensitivity profile of P. aeruginosa to Imipenem 
from January 2004 to December 2008.
Figure 4: Sensitivity profile of P. aeruginosa to Meropenem 
from January 2004 to December 2008.
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DISCUSSION
There are a large number and variety of new resistance 
mechanisms that have emerged and their preliminary detec-
tion is important for infection control and adequate thera-
peutic guidance.
Among the resistance mechanisms to carbapenems de-
scribed for P. aeruginosa and A. baumanii can be highlighted 
β-lactamases production, efﬂ ux pump and loss of porins 
can be highlighted.
β-lactamases have been grouped into four molecular 
classes A, B, C and D, based on the amino acids sequence 
homology according to Ambler classifi cation (1980). The 
ones that belong to A, C and D classes are called serine-
β-lactamases, and the others in B class are called metallo-
β-lactamases (MBL). These enzymes have the common 
property of hydrolyzing; at least partially, imipenem or 
meropenem, besides they hydrolyze other penicillins and 
cephalosporins.8,22 
β-lactamases have been grouped into four molecular 
classes, namely A, B, C and D, based on the amino acids 
sequence homology according to Ambler classification 
(1980)1. A, C and D classes are called serine-β-lactamases, 
and B class β-lactamases are refered to as metallo-β-
lactamases (MBL). These enzymes have the common 
property of hydrolyzing; at least partially, imipenem or 
meropenem, besides hydrolyzing other penicillins and 
cephalosporins.8 
In Brazil, the fi rst report of acquired MBL was in 1997, 
in a sample with P. aeruginosa, reported as SPM-1 variant 
at the São Paulo Hospital/UNIFESP. In 1998, in the same 
hospital, samples of Acinetobacter spp with resistance or re-
duced sensitivity to carbapenems were isolated. Out of those, 
54% (40/73) were IMP-1 producers. In 2003, a sample of A. 
baumannii presenting IMP variant was isolated which was 
resistant to imipenem, meropenem and broad-spectrum 
cephalosporins.6,20,21 
Resistance of P. aerugionsa and A. baumannii to Carbap-
enems may result from changes in the penicillin-binding 
proteins and porins. Since carbapenems enter the bacterium 
through the porins, one could postulate that porins changes 
could be involved in the resistance to these antibiotics.10,12,14
Efﬂ ux pumps are a unique resistance mechanism against 
different classes of antimicrobials. AdeABC efﬂ ux pump, 
characterized in A. baumannii, together with the over-ex-
pression oxacilinases can result in resistance to carbapen-
ems.14 In P. aeruginosa, the MexA-MexB-OprM efﬂ ux pump 
is responsible for antimicrobial transport to the external side 
of the bacterial cell.9,11
At Saint Joseph Martin Hospital in Buenos Aires from 
1998 to 2001, Rodriguez et al., reported 60% of Acineto-
bacter spp resistance to imipenem. Furthermore, P. aeru-
ginosa showed an increasing resistance to imipenem from 
15.4% to 68%.
A Latin America multicenter study, the SENTRY - An-
timicrobial Surveillance Program – reported in 2001 Aci-
netobacter spp. resistance rates to imipenem of 16.7% and to 
meropenem of 18.17%. P. aeruginosa presented resistance of 
37.8% to imipenem and 35.6% to meropenem.16,17
The data obtained showed a signifi cant increase of A. 
baumannii carbapenems resistance from 2005, whereas P. 
aeruginosa did not present statistically signifi cant differ-
ence over the years. Molecular studies are essential to unfold 
resistance mechanisms, mainly associated to A. baumanii. 
Likewise, they will be useful to evaluate a possible cloned 
dissemination in the hospital environment.
CONCLUSION
New bacterial resistance patterns have emerged, and the 
gathering of different enzymes in different bacterial species 
shows the real potential for dissemination of these genetic 
elements and causes great concern.
The data presented showed high rates of Pseudomonas 
aeruginosa and Acinetobacter baumannii resistant to carbap-
enems, reducing the availability of effective agents. The fi ght 
against these microorganisms in hospitals can be accom-
plished through the constant presence of the hospital infec-
tion control committee, recognizing the local microbiota 
and having protocols for a rational use of antimicrobials.
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